ScholarIQanswers from OpenAlex & ORCID
David Langleben
ResearcherPublications, citations & collaboration network
David Langleben is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Langleben have?
ScholarIQindexed works
David Langleben has 267 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Langleben have?
ScholarIQcitation count
David Langleben has 21,935 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Langleben?
ScholarIQh-index
David Langleben has an h-index of 49 in OpenAlex.
What is the i10-index of David Langleben?
ScholarIQi10-index
David Langleben has an i10-index of 121 in OpenAlex.
What is the ORCID of David Langleben?
ScholarIQorcid
The ORCID for David Langleben is on the source record.
What is the OpenAlex record for David Langleben?
ScholarIQopenalex
The OpenAlex for David Langleben is on the source record.
What are the most-cited papers on David Langleben?
ScholarIQmost cited works
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst, Lewis J. Rubin, Walker Long, Michael D. McGoon, Stuart Rich, David B. Badesch, Bertron Μ. Groves, Victor F. Tapson, Robert C. Bourge, Bruce H. Brundage, Spencer K. Koerner, David Langleben, Cesar A. Keller, Srinivas Murali, Barry F. Uretsky, Linda Clayton, Maria M. Jöbsis, Shelmer D. Blackburn, Denise Shortino, James W. Crow
Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension
Adel Giaid, Masashi Yanagisawa, David Langleben, René P. Michel, Robert D. Levy, Hani Shennib, Sadao Kimura, Τοmoh Masaki, William P. Duguid, Duncan J. Stewart
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, Marc Humbert, Zhi‐Cheng Jing, Anne Keogh, David Langleben, Michael Ochan Kilama, Arno Fritsch, D. Neuser, Lewis J. Rubin
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
David B. Badesch, Victor F. Tapson, Michael D. McGoon, Bruce H. Brundage, Lewis J. Rubin, Fredrick M. Wigley, Stuart Rich, Robyn J. Barst, Pamela S. Barrett, Kenneth M. Kral, Maria M. Jöbsis, James E. Loyd, Srinivas Murali, Adaani Frost, Reda E. Girgis, Robert C. Bourge, David Ralph, C. Gregory Elliott, Nicholas S. Hill, David Langleben, Robert Schilz, Vallerie V. McLaughlin, Ivan M. Robbins, Bertron Μ. Groves, Shelley Shapiro, Thomas A. Medsger, Seán Gaine, Evelyn M. Horn, James C. Decker, Katharine Knobil
Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension
Alan L. Hinderliter, Park W. Willis, Robyn J. Barst, Stuart Rich, Lewis J. Rubin, David B. Badesch, Bertron Μ. Groves, Michael D. McGoon, Victor F. Tapson, Robert C. Bourge, Bruce H. Brundage, Spencer K. Koerner, David Langleben, Cesar A. Keller, Srinivas Murali, Barry F. Uretsky, Gary G. Koch, Shu Li, Linda Clayton, Maria M. Jöbsis, Shelmer D. Blackburn, James W. Crow, Walker Long